Materiały źródłowe

• #1 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  Synovial sarcoma accounts for up to 10% of all STS. In the US, 800-1000 new cases of SS are diagnosed annually. According to an analysis of the Surveillance, Epidemiology, and End Results (SEER) database study, the age-adjusted incidence rate of SS in the US is 0.177 per 100,000 (approximately 580 incident cases) with a prevalence rate of 0.65 per 100,000 (approximately 2129 prevalent cases). […] Although SS can affect any age, it is known to occur more commonly in adolescents and adults younger than 30. SS is considered the most common sarcoma in the adolescent age group.

• #2 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. […] In children, SS is the most common nonrhabdomyosarcoma STS, accounting for 26%-36% of these cancers. […] An estimated 800-1000 new SS cases per year occur in both the United States and the European Union. […] In a recent nationwide database study in France (2013-2016), SS had a yearly incidence of 1.67 cases per million. […] Similarly, in the United States, an estimated one to two people per million are diagnosed with SS annually. […] A study on patients registered in the Surveillance, Epidemiology, and End Results (SEER) database determined that the age-adjusted incidence of SS was greater in adults than in children (1.42 versus 0.81 per million individuals, respectively).

• #3 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. […] In children, SS is the most common nonrhabdomyosarcoma STS, accounting for 26%-36% of these cancers. […] An estimated 800-1000 new SS cases per year occur in both the United States and the European Union. […] In a recent nationwide database study in France (2013-2016), SS had a yearly incidence of 1.67 cases per million. […] Similarly, in the United States, an estimated one to two people per million are diagnosed with SS annually. […] A study on patients registered in the Surveillance, Epidemiology, and End Results (SEER) database determined that the age-adjusted incidence of SS was greater in adults than in children (1.42 versus 0.81 per million individuals, respectively).

• #4 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. […] In children, SS is the most common nonrhabdomyosarcoma STS, accounting for 26%-36% of these cancers. […] An estimated 800-1000 new SS cases per year occur in both the United States and the European Union. […] In a recent nationwide database study in France (2013-2016), SS had a yearly incidence of 1.67 cases per million. […] Similarly, in the United States, an estimated one to two people per million are diagnosed with SS annually. […] A study on patients registered in the Surveillance, Epidemiology, and End Results (SEER) database determined that the age-adjusted incidence of SS was greater in adults than in children (1.42 versus 0.81 per million individuals, respectively).

• #5 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. […] In children, SS is the most common nonrhabdomyosarcoma STS, accounting for 26%-36% of these cancers. […] An estimated 800-1000 new SS cases per year occur in both the United States and the European Union. […] In a recent nationwide database study in France (2013-2016), SS had a yearly incidence of 1.67 cases per million. […] Similarly, in the United States, an estimated one to two people per million are diagnosed with SS annually. […] A study on patients registered in the Surveillance, Epidemiology, and End Results (SEER) database determined that the age-adjusted incidence of SS was greater in adults than in children (1.42 versus 0.81 per million individuals, respectively).

• #6 Survival changes in Patients with Synovial Sarcoma, 1983-2012

  https://www.jcancer.org/v08p1759.htm

  Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents. […] To evaluate changes in incidence and survival in SyS over three decades, we accessed data on SyS cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results (SEER) database. […] Our study demonstrated that the incidence of SyS per 1,000,000 continued to increase from 0.906 to 1.348 to 1.548 in the total population and in most age groups and that the age of incidence peak was 15-29 years in three decades. […] But, the survival of patients with SyS did not significantly improve throughout the three decades, with 5-year survival rates of 69.4%, 61.1% and 60.5% respectively (p<0.05). [...] This study demonstrated the increasing incidence and unimproved survival rates across three decades in a large sample, indicating the urgency for further development of diagnosis, improving health care providers' awareness of SyS and lead to the development of novel treatments.

• #7 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  Synovial sarcoma accounts for up to 10% of all STS. In the US, 800-1000 new cases of SS are diagnosed annually. According to an analysis of the Surveillance, Epidemiology, and End Results (SEER) database study, the age-adjusted incidence rate of SS in the US is 0.177 per 100,000 (approximately 580 incident cases) with a prevalence rate of 0.65 per 100,000 (approximately 2129 prevalent cases). […] Although SS can affect any age, it is known to occur more commonly in adolescents and adults younger than 30. SS is considered the most common sarcoma in the adolescent age group.

• #8 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  Synovial sarcoma accounts for up to 10% of all STS. In the US, 800-1000 new cases of SS are diagnosed annually. According to an analysis of the Surveillance, Epidemiology, and End Results (SEER) database study, the age-adjusted incidence rate of SS in the US is 0.177 per 100,000 (approximately 580 incident cases) with a prevalence rate of 0.65 per 100,000 (approximately 2129 prevalent cases). […] Although SS can affect any age, it is known to occur more commonly in adolescents and adults younger than 30. SS is considered the most common sarcoma in the adolescent age group.

• #9 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. […] In children, SS is the most common nonrhabdomyosarcoma STS, accounting for 26%-36% of these cancers. […] An estimated 800-1000 new SS cases per year occur in both the United States and the European Union. […] In a recent nationwide database study in France (2013-2016), SS had a yearly incidence of 1.67 cases per million. […] Similarly, in the United States, an estimated one to two people per million are diagnosed with SS annually. […] A study on patients registered in the Surveillance, Epidemiology, and End Results (SEER) database determined that the age-adjusted incidence of SS was greater in adults than in children (1.42 versus 0.81 per million individuals, respectively).

• #10 Synovial sarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/synovial-sarcoma?case_id=synovial-sarcoma-2

  Synovial sarcomas typically present in adolescents and young adults (15-40 years of age). There may be a mild male predilection (M:F = 1.2:1). They account for 2.5-10% of all soft tissue sarcoma 2-4. […] Overall 5-year survival is between 36-76%. Both local recurrence (30-50%) and distant metastases are frequent (40-70%), most commonly to the lungs as cannonball metastases (~80%), bones (~15%), regional lymph nodes (~10%), followed by chest wall/abdomen (~7.5%) 7,8.

• #11 Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. | Read by QxMD

  https://read.qxmd.com/read/32618221/epidemiology-incidence-and-survival-of-synovial-sarcoma-subtypes-seer-database-analysis?redirected=slug

  Synovial sarcoma (SyS) is a rare malignancy that is typically located on the limbs and occurs predominantly in adolescents. A total of 3228 patients were included, with a mean age of 39.3 18.8 (range: 1-94), of which 1521 (47.1%) were females and 1707 (52.9%) were males. According to its subtypes, 47.2% were SyS not otherwise specified, 32.3% were spindle cell, 19.9% were biphasic, and 0.6% were epithelioid type. The overall survival period is 138.0 (95% confidence interval: 113.2-162.8) months. Survival duration was found to be significantly different between groups according to gender (log-rank test; p 0.001), age groups (log-rank test; p 0.001), race (log-rank test; p = 0.001), marital status (log-rank test; p 0.001), tumor subtypes (log-rank test; p 0.001), tumor location (log-rank test; p 0.001), tumor laterality (log-rank test; p 0.001), date of diagnosis (log-rank test; p = 0.025), tumor grade (log-rank test; p 0.001), historic stage (log-rank test; p 0.001), state of chemotherapy (log-rank test; p 0.001), state of radiotherapy (log-rank test; p 0.001), presence of metastasis (log-rank test; p 0.001), and total number of malignant tumors (log-rank test; p 0.001). Male gender, being colored individual, being over 35 years at the time of diagnosis, epithelioid type, non-head and neck region localization is associated with poor prognosis. While radiotherapy improves survival, benefit of chemotherapy is unclear.

• #12 Synovial Sarcoma – SFA

  https://curesarcoma.org/sarcoma-subtypes/synovial-sarcoma/

  Synovial sarcoma may occur at any age and is equally distributed between the sexes. More than half of the patients are adolescents or young adults, and 77% of cases occur before the age of 50 years. The relative frequency of synovial sarcoma compared with other soft tissue sarcomas is age-dependent, ranging from 15% in patients aged 10–18 years to 1.6% in patients aged > 50 years. […] SS18-SSX1 SSs show an approximately even sex ratio, whereas SS18-SSX2 SSs are significantly more common in women.

• #13 Synovial Sarcoma: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1257131-overview

  In a cross-sectional study using data from Surveillance, Epidemiology, and End Results (SEER) 17 Registries, Patel et al determined that the incidence of primary synovial sarcoma in the United States between 2000 and 2020 was 0.15 per 100,000. The lower extremity was the most common primary tumor site, followed by the upper extremity, the abdomen and pelvis, the internal thorax, and the head and neck. Synovial sarcoma represents around 5-10% of all soft-tissue sarcomas. It is the third most common soft-tissue tumor in adolescents and young adults. […] In anorther study (N = 130) using data from the SEER database, Zhu et al found that in children with synovial sarcoma, factors associated with poorer overall and cancer-specific survival were chemotherapy (possibly because of the selection bias in chemotherapy, whereby patients receiving chemotherapy tend also to have concurrent metastases and a poor prognosis) and worse SEER stage.

• #14 Synovial Sarcoma in the Extremity: Diversity of Imaging Features for Diagnosis and Prognosis

  https://www.mdpi.com/2072-6694/15/19/4860

  Synovial sarcomas are the fourth most prevalent soft-tissue sarcoma, primarily affecting the extremities (in 80–95% of cases) of adolescents and young adults aged 15 to 40. […] According to data from the SEER (Surveillance, Epidemiology, and End Results) database, synovial sarcomas are primarily diagnosed during the third decade of life, with only a small portion (2.5%) of cases occurring in children under the age of 10. […] Approximately 80% to 95% of synovial sarcomas manifest in the extremities, with the intrathoracic and head and neck regions being less frequently affected. […] The gradual rate of growth can give rise to a deceptive perception of benignity, which could potentially lead to delays in the diagnostic process. […] However, synovial sarcomas display aggressive behavior, evidenced by local recurrence rates up to 50%, with as many as a quarter of patients developing distant metastases.

• #15

  https://www.orthobullets.com/pathology/8052/synovial-sarcoma

  Synovial Sarcoma is a malignant, soft tissue sarcoma caused by a t(X;18) chromosomal translocation mutation ( SS18:SSX fusion protein) most commonly found near joints but rarely within the joint. […] The condition usually presents in patients between 15 and 40 years old with a growing mass in proximity to a joint. […] Epidemiology: 5-10% of all soft tissue sarcomas. […] most common sarcoma found in adolescent age group. […] affects males and females almost equally (1.2 to 1). […] More common in the lower limbs, most commonly around the knee – popliteal fossa. […] it is the most common sarcoma of the foot.

• #16 Synovial sarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/synovial-sarcoma?case_id=synovial-sarcoma-2

  Synovial sarcomas typically present in adolescents and young adults (15-40 years of age). There may be a mild male predilection (M:F = 1.2:1). They account for 2.5-10% of all soft tissue sarcoma 2-4. […] Overall 5-year survival is between 36-76%. Both local recurrence (30-50%) and distant metastases are frequent (40-70%), most commonly to the lungs as cannonball metastases (~80%), bones (~15%), regional lymph nodes (~10%), followed by chest wall/abdomen (~7.5%) 7,8.

• #17 Synovial Sarcoma – NCI

  https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/synovial-sarcoma

  Synovial sarcoma is a cancer that can come from different types of soft tissue, such as muscle or ligaments. It is often found in the arm, leg, or foot, and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen. Synovial sarcoma may also be called malignant synovioma. […] One third of patients with synovial sarcoma will be diagnosed under the age of 30. It is somewhat more common in males. […] Synovial sarcoma accounts for 5% to 10% of soft-tissue tumors. For every one million people, one to two are diagnosed with synovial sarcoma per year in the US. […] Doctors estimate synovial sarcoma survival rates by how groups of people with synovial sarcoma have done in the past. Given that there are so few synovial sarcoma patients, survival rates may not be very accurate. They also dont consider newer treatments being developed. We know that anywhere from 36% to 76% of people with synovial sarcoma will be alive five years after their first diagnosis. Chances of survival are better if the tumor is completely removed and does not return or spread.

• #18 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  The 5-year cancer-specific survival (CSS) rates are 60% in adults and 80% in younger patients. […] Compared with those presenting with localized disease, patients with advanced SS at initial diagnosis have a poor prognosis. […] Adults with metastatic SS at diagnosis have a 5-year overall survival (OS) rate of 10% versus 76% for those with localized disease at diagnosis. […] A risk-based prospective trial in children and young adults 30 years of age with SS recorded greater 5-year EFS and OS rates in the low-risk (localized disease) treatment arm when compared with the high-risk (metastatic disease) arm (82% and 98% versus 8% and 13%, respectively). […] The recent retrospective nationwide METASYN study from the FSG reported real-world treatment outcomes for metastatic SS in 417 patients. […] In the metastatic setting, 75.3% of patients received first-line systemic chemotherapy and a median of three lines of treatment. […] The ORR with first-line chemotherapy was 39.2%, with a median PFS of 6 months (95% CI 5.26-7.36 months).

• #19 Synovial sarcoma: current perspectives | COAYA

  https://www.dovepress.com/synovial-sarcoma-current-perspectives-peer-reviewed-fulltext-article-COAYA

  Synovial sarcoma (SS) is a distinct soft tissue sarcoma, occurring across all ages, from young children to the elderly, but the incidence of SS peaks in young adults. […] The incidence, however, in the context of STSs in adults is low, accounting for 10% overall. […] The role of age as a prognostic factor has been examined in single institutional studies, the US population-based Surveillance Epidemiology, the End Results (SEER) cancer registry, and the English national cancer registry. […] From the English national cancer registry data, the 5-year relative survival rate for the whole series across all ages from 1985 to 2008 was 56% (95% CI: 47%64%). […] There were, however, significant differences (P0.05) in the 5-year relative survival rates between those patients aged 0-19 years and those patients aged 20 years, 72% (95% CI: 46%88%) vs 53% (95% CI: 44%; 62%), respectively.

• #20 Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005

  https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W1977144004

  Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005 […] Synovial sarcoma (SS) is a typical soft tissue sarcoma subtype crosswise between the pediatric and the adult age groups. Less satisfactory overall outcome has been recorded in adult series. This study compares clinical features and outcomes of SS across the different age groups, by analyzing 1268 cases, 213 children/adolescents (or=18 years) and 1055 adults, registered in the Surveillance, Epidemiology, and End Results (SEER) 17 database from 1983 to 2005. […] The estimated 5-year cancer-specific survival was 83% for children/adolescents and 62% for adults (P.001). […] In multivariate analysis, adult patients had significantly higher mortality rates than children after adjusting for other variables. […] Children and adults with SS have a similar clinical presentation but a dissimilar outcome, suggesting that factors other than unfavorable clinical features might be involved in the unsatisfactory outcome of adult SS patients.

• #21 Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10470271/

  The 5-year cancer-specific survival (CSS) rates are 60% in adults and 80% in younger patients. […] Compared with those presenting with localized disease, patients with advanced SS at initial diagnosis have a poor prognosis. […] Adults with metastatic SS at diagnosis have a 5-year overall survival (OS) rate of 10% versus 76% for those with localized disease at diagnosis. […] A risk-based prospective trial in children and young adults 30 years of age with SS recorded greater 5-year EFS and OS rates in the low-risk (localized disease) treatment arm when compared with the high-risk (metastatic disease) arm (82% and 98% versus 8% and 13%, respectively). […] The recent retrospective nationwide METASYN study from the FSG reported real-world treatment outcomes for metastatic SS in 417 patients. […] In the metastatic setting, 75.3% of patients received first-line systemic chemotherapy and a median of three lines of treatment. […] The ORR with first-line chemotherapy was 39.2%, with a median PFS of 6 months (95% CI 5.26-7.36 months).

• #22 Age as an independent prognostic factor for survival of localised synovial sarcoma patients | British Journal of Cancer

  https://www.nature.com/articles/bjc2015375

  We performed a retrospective nationwide study to explore age as a prognostic factor in synovial sarcoma patients. […] The current epidemiological analysis reflects real-life management. Stage at diagnosis is a known prognostic factor, with a reported 69% 10-year cancer-specific survival in patients with local disease at diagnosis, dropping to 8.9% in patients with metastasis at diagnosis. […] Several retrospective studies in patients with localised disease have looked at age as a prognostic factor for survival, with children having a more favourable outcome compared with adult synovial sarcoma patients. […] The multivariable analysis identified older age, larger tumour size, and primary tumour localisation in the trunk as independent prognostic factors for worse OS in synovial sarcoma patients. […] Our study demonstrated that outcomes of patients with synovial sarcoma significantly decrease with age regardless of primary tumour site, size, and treatment.

• #23 Synovial Sarcoma: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1257131-overview

  In a study (N = 3228; mean age, 39.3 18.8 y; 47.1% female, 52.9% male) using data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI), Aytekin et al found that factors associated with a poorer prognosis were male sex, being a person of color, age greater than 35 years at the time of diagnosis, epithelioid type, and localization outside the head and neck region. RT improved survival, but the benefit of chemotherapy was unclear.

• #24 Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. | Read by QxMD

  https://read.qxmd.com/read/32618221/epidemiology-incidence-and-survival-of-synovial-sarcoma-subtypes-seer-database-analysis?redirected=slug

  Synovial sarcoma (SyS) is a rare malignancy that is typically located on the limbs and occurs predominantly in adolescents. A total of 3228 patients were included, with a mean age of 39.3 18.8 (range: 1-94), of which 1521 (47.1%) were females and 1707 (52.9%) were males. According to its subtypes, 47.2% were SyS not otherwise specified, 32.3% were spindle cell, 19.9% were biphasic, and 0.6% were epithelioid type. The overall survival period is 138.0 (95% confidence interval: 113.2-162.8) months. Survival duration was found to be significantly different between groups according to gender (log-rank test; p 0.001), age groups (log-rank test; p 0.001), race (log-rank test; p = 0.001), marital status (log-rank test; p 0.001), tumor subtypes (log-rank test; p 0.001), tumor location (log-rank test; p 0.001), tumor laterality (log-rank test; p 0.001), date of diagnosis (log-rank test; p = 0.025), tumor grade (log-rank test; p 0.001), historic stage (log-rank test; p 0.001), state of chemotherapy (log-rank test; p 0.001), state of radiotherapy (log-rank test; p 0.001), presence of metastasis (log-rank test; p 0.001), and total number of malignant tumors (log-rank test; p 0.001). Male gender, being colored individual, being over 35 years at the time of diagnosis, epithelioid type, non-head and neck region localization is associated with poor prognosis. While radiotherapy improves survival, benefit of chemotherapy is unclear.

• #25 Synovial Sarcoma: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1257131-overview

  In a study (N = 3228; mean age, 39.3 18.8 y; 47.1% female, 52.9% male) using data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI), Aytekin et al found that factors associated with a poorer prognosis were male sex, being a person of color, age greater than 35 years at the time of diagnosis, epithelioid type, and localization outside the head and neck region. RT improved survival, but the benefit of chemotherapy was unclear.

• #26 Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. | Read by QxMD

  https://read.qxmd.com/read/32618221/epidemiology-incidence-and-survival-of-synovial-sarcoma-subtypes-seer-database-analysis?redirected=slug

  Synovial sarcoma (SyS) is a rare malignancy that is typically located on the limbs and occurs predominantly in adolescents. A total of 3228 patients were included, with a mean age of 39.3 18.8 (range: 1-94), of which 1521 (47.1%) were females and 1707 (52.9%) were males. According to its subtypes, 47.2% were SyS not otherwise specified, 32.3% were spindle cell, 19.9% were biphasic, and 0.6% were epithelioid type. The overall survival period is 138.0 (95% confidence interval: 113.2-162.8) months. Survival duration was found to be significantly different between groups according to gender (log-rank test; p 0.001), age groups (log-rank test; p 0.001), race (log-rank test; p = 0.001), marital status (log-rank test; p 0.001), tumor subtypes (log-rank test; p 0.001), tumor location (log-rank test; p 0.001), tumor laterality (log-rank test; p 0.001), date of diagnosis (log-rank test; p = 0.025), tumor grade (log-rank test; p 0.001), historic stage (log-rank test; p 0.001), state of chemotherapy (log-rank test; p 0.001), state of radiotherapy (log-rank test; p 0.001), presence of metastasis (log-rank test; p 0.001), and total number of malignant tumors (log-rank test; p 0.001). Male gender, being colored individual, being over 35 years at the time of diagnosis, epithelioid type, non-head and neck region localization is associated with poor prognosis. While radiotherapy improves survival, benefit of chemotherapy is unclear.

• #27 Synovial Sarcoma: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1257131-overview

  In a study (N = 3228; mean age, 39.3 18.8 y; 47.1% female, 52.9% male) using data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI), Aytekin et al found that factors associated with a poorer prognosis were male sex, being a person of color, age greater than 35 years at the time of diagnosis, epithelioid type, and localization outside the head and neck region. RT improved survival, but the benefit of chemotherapy was unclear.

• #28 Synovial Sarcoma: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1257131-overview

  In a study (N = 3228; mean age, 39.3 18.8 y; 47.1% female, 52.9% male) using data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI), Aytekin et al found that factors associated with a poorer prognosis were male sex, being a person of color, age greater than 35 years at the time of diagnosis, epithelioid type, and localization outside the head and neck region. RT improved survival, but the benefit of chemotherapy was unclear.

• #29 Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. | Read by QxMD

  https://read.qxmd.com/read/32618221/epidemiology-incidence-and-survival-of-synovial-sarcoma-subtypes-seer-database-analysis?redirected=slug

  Synovial sarcoma (SyS) is a rare malignancy that is typically located on the limbs and occurs predominantly in adolescents. A total of 3228 patients were included, with a mean age of 39.3 18.8 (range: 1-94), of which 1521 (47.1%) were females and 1707 (52.9%) were males. According to its subtypes, 47.2% were SyS not otherwise specified, 32.3% were spindle cell, 19.9% were biphasic, and 0.6% were epithelioid type. The overall survival period is 138.0 (95% confidence interval: 113.2-162.8) months. Survival duration was found to be significantly different between groups according to gender (log-rank test; p 0.001), age groups (log-rank test; p 0.001), race (log-rank test; p = 0.001), marital status (log-rank test; p 0.001), tumor subtypes (log-rank test; p 0.001), tumor location (log-rank test; p 0.001), tumor laterality (log-rank test; p 0.001), date of diagnosis (log-rank test; p = 0.025), tumor grade (log-rank test; p 0.001), historic stage (log-rank test; p 0.001), state of chemotherapy (log-rank test; p 0.001), state of radiotherapy (log-rank test; p 0.001), presence of metastasis (log-rank test; p 0.001), and total number of malignant tumors (log-rank test; p 0.001). Male gender, being colored individual, being over 35 years at the time of diagnosis, epithelioid type, non-head and neck region localization is associated with poor prognosis. While radiotherapy improves survival, benefit of chemotherapy is unclear.

• #30 Epidemiology, incidence, and survival of synovial sarcoma of children: a SEER database analysis – Zhu – Translational Pediatrics

  https://tp.amegroups.org/article/view/126976/html

  In summary, chemotherapy, and worse SEER stage were associated with poorer overall and cancer special survivals. […] Chemotherapy and in distant of Surveillance, Epidemiology, and End Results (SEER) stage were associated with poorer overall survival rates in patients with synovial sarcoma (SS). […] Factors such as male, primary tumor site in soft tissue, chemotherapy treatment, in distant of SEER stage, and the absence of surgery were associated with a poorer prognosis in children with SS. […] At the time of diagnosis, just over half of children with SS have localized disease. We come to the conclusion that a bad prognosis is connected with the male gender, being under 5 years old at the time of diagnosis, non-soft tissue localization, chemotherapy, and a worse SEER stage.

• #31 Epidemiology, incidence, and survival of synovial sarcoma of children: a SEER database analysis – Zhu – Translational Pediatrics

  https://tp.amegroups.org/article/view/126976/html

  Roughly 5% to 10% of soft tissue sarcomas fall under the category of synovial sarcomas (SSs), a rare and malignant tumor originating from soft tissues with unclear differentiation, primarily affecting teenagers and young adults. […] The goal of this study was to assess the latest survival rates for SS of children and the risk factors affecting survival using the Surveillance, Epidemiology and End Results (SEER) database. […] A total of 130 patients were enrolled in the study. In the overall survival analysis, age (P=0.01), male (P=0.04), no surgery (P0.01), chemotherapy (P0.01), primary tumor site in soft tissue (P=0.02), and in distant of SEER stage (P0.01) were associated with a worse prognosis in children with SS. […] Multivariate analysis showed that chemotherapy and in distant of SEER stage were independent indicators of unfavorable prognosis.

• #32 Synovial sarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/synovial-sarcoma?case_id=synovial-sarcoma-2

  Synovial sarcomas typically present in adolescents and young adults (15-40 years of age). There may be a mild male predilection (M:F = 1.2:1). They account for 2.5-10% of all soft tissue sarcoma 2-4. […] Overall 5-year survival is between 36-76%. Both local recurrence (30-50%) and distant metastases are frequent (40-70%), most commonly to the lungs as cannonball metastases (~80%), bones (~15%), regional lymph nodes (~10%), followed by chest wall/abdomen (~7.5%) 7,8.

• #33 Synovial sarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/synovial-sarcoma?case_id=synovial-sarcoma-2

  Synovial sarcomas typically present in adolescents and young adults (15-40 years of age). There may be a mild male predilection (M:F = 1.2:1). They account for 2.5-10% of all soft tissue sarcoma 2-4. […] Overall 5-year survival is between 36-76%. Both local recurrence (30-50%) and distant metastases are frequent (40-70%), most commonly to the lungs as cannonball metastases (~80%), bones (~15%), regional lymph nodes (~10%), followed by chest wall/abdomen (~7.5%) 7,8.

• #34 Synovial Sarcoma | UCSF Department of Surgery

  https://surgicaloncology.ucsf.edu/condition/synovial-sarcoma

  Synovial sarcoma occurs most commonly in the younger patients under 30 years of age. While overall comprising about 8% of all soft tissue sarcomas, it accounts for 15-20% of the cases in adolescents and young adults. […] After treatment, surveillance includes regular imaging such as CT scans to detect recurrences at either the area of the original tumor or distant sites in the body (metastatic disease) such as the lungs, which are the most common site for synovial sarcoma metastases. Less than 10% of patients have detectable metastases at the time of initial diagnosis.

• #35 Synovial Sarcoma: A Clinical Review

  https://www.mdpi.com/1718-7729/28/3/177

  Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. […] The age-adjusted incidence is 0.81/1,000,000 in children and 1.42/1,000,000 in adults with approximately 1000 patients diagnosed with synovial sarcoma in the United States each year. […] Synovial sarcomas are malignant and metastasize, most commonly to the lungs with up to 13% of patients having distant metastases at the time of diagnosis. […] However, these findings were based on small case series and more recent Surveillance, Epidemiology and End Results (SEER) database findings suggest that the rates of lymph node metastases are in line with other STS and do not require additional workup beyond thorough physical examination. […] The current literature suggests the five-year survival rates ranges from 59–75%. […] Local and metastatic relapse of soft-tissue sarcomas generally occur in the first two years following treatment and thus surveillance and follow-up is most intensive in this period. […] However, synovial sarcoma is unique in this regard in that it tends to recur much later.

• #36 Synovial Sarcoma: A Clinical Review

  https://www.mdpi.com/1718-7729/28/3/177

  Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. […] The age-adjusted incidence is 0.81/1,000,000 in children and 1.42/1,000,000 in adults with approximately 1000 patients diagnosed with synovial sarcoma in the United States each year. […] Synovial sarcomas are malignant and metastasize, most commonly to the lungs with up to 13% of patients having distant metastases at the time of diagnosis. […] However, these findings were based on small case series and more recent Surveillance, Epidemiology and End Results (SEER) database findings suggest that the rates of lymph node metastases are in line with other STS and do not require additional workup beyond thorough physical examination. […] The current literature suggests the five-year survival rates ranges from 59–75%. […] Local and metastatic relapse of soft-tissue sarcomas generally occur in the first two years following treatment and thus surveillance and follow-up is most intensive in this period. […] However, synovial sarcoma is unique in this regard in that it tends to recur much later.

• #37 Synovial Sarcoma in the Extremity: Diversity of Imaging Features for Diagnosis and Prognosis

  https://www.mdpi.com/2072-6694/15/19/4860

  Five-year survival rates range from 24% to 71%, influenced by a range of prognostic factors, including age, location, and histological grades. […] Notably, it is important to acknowledge that delayed local recurrences and metastases occurring more than 5 years after the initial diagnosis are common, which might necessitate extended follow-up periods. […] Numerous clinical and pathological prognostic factors have been documented. These include factors like patient age, tumor size, tumor grade, histologic subtypes, anatomical location, the effectiveness of local treatments with negative surgical margins, and the use of additional treatments such as adjuvant radiotherapy. […] Notably, patient under the age of 15 to 20 years tend to have a more favorable long-term prognosis. […] Among these factors, the size of the tumor at presentation, particularly tumors larger than 5 cm, significantly influences prognosis.

• #38 Post-operative surveillance in soft tissue sarcoma: using tumorspecific recurrence patterns to direct approach – Zaidi – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/20903/html

  Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. […] Although surveillance protocols have been developed in parallel with our growing knowledge of cancer biology, many of these surveillance programs lack evidence for their effectiveness in detecting local or distant recurrences at a treatable stage. This is especially true in soft tissue sarcoma (STS), where the complex heterogeneity of the disease presents particular challenges in crafting effective surveillance strategies. […] STS remains a rare malignancy even in centers specializing in cancer care, which makes crafting effective surveillance strategies difficult. […] Unique obstacles exist in creating surveillance strategies for STS due mainly to the diverse natural history and recurrence patterns between tumor subtypes. In recent years however, multiple groups have compiled extended follow-up data on the specific histologic subtypes of STS. In light of this data, we propose using tumor-specific protocols for postoperative surveillance centered around the histologic subtype of each tumor.

• #39 Post-operative surveillance in soft tissue sarcoma: using tumorspecific recurrence patterns to direct approach – Zaidi – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/20903/html

  Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. […] Although surveillance protocols have been developed in parallel with our growing knowledge of cancer biology, many of these surveillance programs lack evidence for their effectiveness in detecting local or distant recurrences at a treatable stage. This is especially true in soft tissue sarcoma (STS), where the complex heterogeneity of the disease presents particular challenges in crafting effective surveillance strategies. […] STS remains a rare malignancy even in centers specializing in cancer care, which makes crafting effective surveillance strategies difficult. […] Unique obstacles exist in creating surveillance strategies for STS due mainly to the diverse natural history and recurrence patterns between tumor subtypes. In recent years however, multiple groups have compiled extended follow-up data on the specific histologic subtypes of STS. In light of this data, we propose using tumor-specific protocols for postoperative surveillance centered around the histologic subtype of each tumor.

• #40 Synovial sarcoma with intra-abdominal metastasis causing hemoperitoneum: a case-report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02885-2

  Synovial sarcoma is a rare soft tissue sarcoma which frequently involves the upper or lower extremities. […] The 5-year survival rate in adults ranges from 50 to 60% and the 5-year metastatic disease-free survival is anywhere from 40 to 60%. […] Per NCCN guidelines, follow-up includes history and physical examination every 36 months for 2-3 years then every 6 months for the next 2 years and then annually. […] Of note, for extremity, body wall, and head and neck soft tissue sarcomas, there are currently no guidelines or recommendations for routine surveillance of the abdomen or pelvis and reports of intra-abdominal metastasis are quite rare. […] Unfortunately, guidelines for routine locoregional surveillance as well as recommendations for surveillance of distant metastatic disease are lacking.

• #41 Synovial Sarcoma | UCSF Department of Surgery

  https://surgicaloncology.ucsf.edu/condition/synovial-sarcoma

  Synovial sarcoma occurs most commonly in the younger patients under 30 years of age. While overall comprising about 8% of all soft tissue sarcomas, it accounts for 15-20% of the cases in adolescents and young adults. […] After treatment, surveillance includes regular imaging such as CT scans to detect recurrences at either the area of the original tumor or distant sites in the body (metastatic disease) such as the lungs, which are the most common site for synovial sarcoma metastases. Less than 10% of patients have detectable metastases at the time of initial diagnosis.

• #42 Synovial sarcoma with intra-abdominal metastasis causing hemoperitoneum: a case-report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02885-2

  Given the propensity of the majority of soft tissue sarcomas to metastasize to the lung, surveillance imaging tends to focus on pulmonary imaging with chest-ray or CT scans the mainstays of routine imaging. […] In the case of the previously described patient, she had no symptoms prior to the day of presentation to suggest intra-abdominal pathology or warrant a CT of the abdomen and pelvis which raises the question of whether or not patients with high-risk features may benefit from surveillance imaging of the abdomen and pelvis. […] The role of PET/CT in evaluating soft tissue sarcomas continues to evolve.

• #43 Synovial sarcoma with intra-abdominal metastasis causing hemoperitoneum: a case-report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02885-2

  Synovial sarcoma is a rare soft tissue sarcoma which frequently involves the upper or lower extremities. […] The 5-year survival rate in adults ranges from 50 to 60% and the 5-year metastatic disease-free survival is anywhere from 40 to 60%. […] Per NCCN guidelines, follow-up includes history and physical examination every 36 months for 2-3 years then every 6 months for the next 2 years and then annually. […] Of note, for extremity, body wall, and head and neck soft tissue sarcomas, there are currently no guidelines or recommendations for routine surveillance of the abdomen or pelvis and reports of intra-abdominal metastasis are quite rare. […] Unfortunately, guidelines for routine locoregional surveillance as well as recommendations for surveillance of distant metastatic disease are lacking.

• #44 Synovial sarcoma with intra-abdominal metastasis causing hemoperitoneum: a case-report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02885-2

  Synovial sarcoma is a rare soft tissue sarcoma which frequently involves the upper or lower extremities. […] The 5-year survival rate in adults ranges from 50 to 60% and the 5-year metastatic disease-free survival is anywhere from 40 to 60%. […] Per NCCN guidelines, follow-up includes history and physical examination every 36 months for 2-3 years then every 6 months for the next 2 years and then annually. […] Of note, for extremity, body wall, and head and neck soft tissue sarcomas, there are currently no guidelines or recommendations for routine surveillance of the abdomen or pelvis and reports of intra-abdominal metastasis are quite rare. […] Unfortunately, guidelines for routine locoregional surveillance as well as recommendations for surveillance of distant metastatic disease are lacking.

• #45 Synovial sarcoma with intra-abdominal metastasis causing hemoperitoneum: a case-report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02885-2

  Given the propensity of the majority of soft tissue sarcomas to metastasize to the lung, surveillance imaging tends to focus on pulmonary imaging with chest-ray or CT scans the mainstays of routine imaging. […] In the case of the previously described patient, she had no symptoms prior to the day of presentation to suggest intra-abdominal pathology or warrant a CT of the abdomen and pelvis which raises the question of whether or not patients with high-risk features may benefit from surveillance imaging of the abdomen and pelvis. […] The role of PET/CT in evaluating soft tissue sarcomas continues to evolve.

• #46 Post-operative surveillance in soft tissue sarcoma: using tumorspecific recurrence patterns to direct approach – Zaidi – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/20903/html

  Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. […] Although surveillance protocols have been developed in parallel with our growing knowledge of cancer biology, many of these surveillance programs lack evidence for their effectiveness in detecting local or distant recurrences at a treatable stage. This is especially true in soft tissue sarcoma (STS), where the complex heterogeneity of the disease presents particular challenges in crafting effective surveillance strategies. […] STS remains a rare malignancy even in centers specializing in cancer care, which makes crafting effective surveillance strategies difficult. […] Unique obstacles exist in creating surveillance strategies for STS due mainly to the diverse natural history and recurrence patterns between tumor subtypes. In recent years however, multiple groups have compiled extended follow-up data on the specific histologic subtypes of STS. In light of this data, we propose using tumor-specific protocols for postoperative surveillance centered around the histologic subtype of each tumor.

• #47 Post-operative surveillance in soft tissue sarcoma: using tumorspecific recurrence patterns to direct approach – Zaidi – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/20903/html

  Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. […] Although surveillance protocols have been developed in parallel with our growing knowledge of cancer biology, many of these surveillance programs lack evidence for their effectiveness in detecting local or distant recurrences at a treatable stage. This is especially true in soft tissue sarcoma (STS), where the complex heterogeneity of the disease presents particular challenges in crafting effective surveillance strategies. […] STS remains a rare malignancy even in centers specializing in cancer care, which makes crafting effective surveillance strategies difficult. […] Unique obstacles exist in creating surveillance strategies for STS due mainly to the diverse natural history and recurrence patterns between tumor subtypes. In recent years however, multiple groups have compiled extended follow-up data on the specific histologic subtypes of STS. In light of this data, we propose using tumor-specific protocols for postoperative surveillance centered around the histologic subtype of each tumor.

• #48 Synovial Sarcoma: A Clinical Review

  https://www.mdpi.com/1718-7729/28/3/177

  Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. […] The age-adjusted incidence is 0.81/1,000,000 in children and 1.42/1,000,000 in adults with approximately 1000 patients diagnosed with synovial sarcoma in the United States each year. […] Synovial sarcomas are malignant and metastasize, most commonly to the lungs with up to 13% of patients having distant metastases at the time of diagnosis. […] However, these findings were based on small case series and more recent Surveillance, Epidemiology and End Results (SEER) database findings suggest that the rates of lymph node metastases are in line with other STS and do not require additional workup beyond thorough physical examination. […] The current literature suggests the five-year survival rates ranges from 59–75%. […] Local and metastatic relapse of soft-tissue sarcomas generally occur in the first two years following treatment and thus surveillance and follow-up is most intensive in this period. […] However, synovial sarcoma is unique in this regard in that it tends to recur much later.

• #49 Post-operative surveillance in soft tissue sarcoma: using tumorspecific recurrence patterns to direct approach – Zaidi – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/20903/html

  Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. […] Although surveillance protocols have been developed in parallel with our growing knowledge of cancer biology, many of these surveillance programs lack evidence for their effectiveness in detecting local or distant recurrences at a treatable stage. This is especially true in soft tissue sarcoma (STS), where the complex heterogeneity of the disease presents particular challenges in crafting effective surveillance strategies. […] STS remains a rare malignancy even in centers specializing in cancer care, which makes crafting effective surveillance strategies difficult. […] Unique obstacles exist in creating surveillance strategies for STS due mainly to the diverse natural history and recurrence patterns between tumor subtypes. In recent years however, multiple groups have compiled extended follow-up data on the specific histologic subtypes of STS. In light of this data, we propose using tumor-specific protocols for postoperative surveillance centered around the histologic subtype of each tumor.

• #50 Survival changes in Patients with Synovial Sarcoma, 1983-2012

  https://www.jcancer.org/v08p1759.htm

  Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents. […] To evaluate changes in incidence and survival in SyS over three decades, we accessed data on SyS cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results (SEER) database. […] Our study demonstrated that the incidence of SyS per 1,000,000 continued to increase from 0.906 to 1.348 to 1.548 in the total population and in most age groups and that the age of incidence peak was 15-29 years in three decades. […] But, the survival of patients with SyS did not significantly improve throughout the three decades, with 5-year survival rates of 69.4%, 61.1% and 60.5% respectively (p<0.05). [...] This study demonstrated the increasing incidence and unimproved survival rates across three decades in a large sample, indicating the urgency for further development of diagnosis, improving health care providers' awareness of SyS and lead to the development of novel treatments.

• #51 Synovial Sarcoma (SS) Epidemiology Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210331005718/en/Synovial-Sarcoma-SS-Epidemiology-Forecast-to-2030-Focus-on-United-States-Germany-Spain-Italy-France-United-Kingdom-and-Japan—ResearchAndMarkets.com

  The „Synovial Sarcoma (SS) – Epidemiology Forecast to 2030” report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018-2030. […] The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020. […] As per the estimates, the United States has the largest incident population of synovial sarcoma. […] Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

• #52 Synovial Sarcoma (SS) Epidemiology Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210331005718/en/Synovial-Sarcoma-SS-Epidemiology-Forecast-to-2030-Focus-on-United-States-Germany-Spain-Italy-France-United-Kingdom-and-Japan—ResearchAndMarkets.com

  The „Synovial Sarcoma (SS) – Epidemiology Forecast to 2030” report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018-2030. […] The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020. […] As per the estimates, the United States has the largest incident population of synovial sarcoma. […] Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

• #53 Synovial Sarcoma (SS) Epidemiology Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210331005718/en/Synovial-Sarcoma-SS-Epidemiology-Forecast-to-2030-Focus-on-United-States-Germany-Spain-Italy-France-United-Kingdom-and-Japan—ResearchAndMarkets.com

  The „Synovial Sarcoma (SS) – Epidemiology Forecast to 2030” report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018-2030. […] The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020. […] As per the estimates, the United States has the largest incident population of synovial sarcoma. […] Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

• #54 Synovial Sarcoma (SS) Epidemiology Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210331005718/en/Synovial-Sarcoma-SS-Epidemiology-Forecast-to-2030-Focus-on-United-States-Germany-Spain-Italy-France-United-Kingdom-and-Japan—ResearchAndMarkets.com

  The „Synovial Sarcoma (SS) – Epidemiology Forecast to 2030” report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018-2030. […] The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020. […] As per the estimates, the United States has the largest incident population of synovial sarcoma. […] Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

• #55 Survival changes in Patients with Synovial Sarcoma, 1983-2012

  https://www.jcancer.org/v08p1759.htm

  Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents. […] To evaluate changes in incidence and survival in SyS over three decades, we accessed data on SyS cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results (SEER) database. […] Our study demonstrated that the incidence of SyS per 1,000,000 continued to increase from 0.906 to 1.348 to 1.548 in the total population and in most age groups and that the age of incidence peak was 15-29 years in three decades. […] But, the survival of patients with SyS did not significantly improve throughout the three decades, with 5-year survival rates of 69.4%, 61.1% and 60.5% respectively (p<0.05). [...] This study demonstrated the increasing incidence and unimproved survival rates across three decades in a large sample, indicating the urgency for further development of diagnosis, improving health care providers' awareness of SyS and lead to the development of novel treatments.

• #56 Primary pulmonary synovial sarcoma – JTCVS Open

  https://www.jtcvsopen.org/article/S2666-2736(22)00068-7/fulltext

  Patients who were diagnosed within the recent decade (2007-2016) did not have a better survival than those diagnosed between 1975 and 2006 (5-year OS of 27.4% vs 32.7%; P= .599 and 5-year DSS of 29.5% vs 34.5%; P= .596). […] The prognosis of PPSS was poorer in the SEER Database comparing with that in our institution. One possible explanation should be that all patients in our institution had no distant metastasis.

• #57 Survival changes in Patients with Synovial Sarcoma, 1983-2012

  https://www.jcancer.org/v08p1759.htm

  Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents. […] To evaluate changes in incidence and survival in SyS over three decades, we accessed data on SyS cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results (SEER) database. […] Our study demonstrated that the incidence of SyS per 1,000,000 continued to increase from 0.906 to 1.348 to 1.548 in the total population and in most age groups and that the age of incidence peak was 15-29 years in three decades. […] But, the survival of patients with SyS did not significantly improve throughout the three decades, with 5-year survival rates of 69.4%, 61.1% and 60.5% respectively (p<0.05). [...] This study demonstrated the increasing incidence and unimproved survival rates across three decades in a large sample, indicating the urgency for further development of diagnosis, improving health care providers' awareness of SyS and lead to the development of novel treatments.

Zobacz więcej